NIH Study Reveals New Mechanism of Mutant RAS Genes in Cancer Growth
NIH researchers reveal new insights into mutant RAS genes and their role in tumor growth, highlighting a previously unknown mechanism that could enhance cancer treatment strategies. Published in Nature Cancer, the study shows how mutant RAS proteins contribute to cancer development by transporting nuclear proteins, suggesting broader implications for various cancers. This groundbreaking discovery may lead to more effective combination therapies for RAS-driven malignancies.
Breakthrough Biologic Drug Targets Mutant HER2 Protein for Cancer Treatment
A groundbreaking study from NYU Langone Health has developed a new biologic drug targeting mutant HER2 proteins, promising effective cancer treatments with minimal side effects. This targeted therapy represents a significant advancement in oncology, paving the way for personalized medicine and improved patient outcomes.